Comparing the safety of two clot-dissolving drugs for acute ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study compares the safety of two clot-dissolving drugs, rhTNK-tPA (Mingfule) and rt-PA (Actilyse), for treating acute ischemic stroke. It aims to see if the newer drug (Mingfule) is as safe as the standard one (Actilyse) when given within 4.5 hours of stroke onset.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have had a stroke due to a blocked blood vessel, confirmed by a CT or MRI scan
- You need to start treatment within 4.5 hours from when your symptoms began (or when you were last seen normal)
- Your stroke severity must be mild to moderate (on a standard scale of 0-42, you must score 25 or less)
- You cannot have any major bleeding risks, such as recent surgery, bleeding in the stomach or brain, or untreated high blood pressure
- You must not have already received a clot-dissolving drug or a clot-removal procedure before arriving at the study hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
This trial compares two clot-busting drugs (tenecteplase or reteplase) given through an IV before a procedure to mechanically remove the clot (thrombectomy) in people with acute ischemic stroke. It aims to see which drug works better to restore blood flow and improve recovery.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-busting drug called tenecteplase given later than usual (4.5 to 9 hours after stroke symptoms) to people whose MRI shows the stroke may still be reversible. The goal is to see if it helps reduce disability after a stroke.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
This trial tests whether a stronger clot-busting drug (tenecteplase) is safe and works for people who have had a stroke while taking a common blood thinner. If you qualify, you may get this treatment within a few hours of your stroke to help improve recovery.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.